Literature DB >> 19074979

Evidence that altered amygdala activity in schizophrenia is related to clinical state and not genetic risk.

Roberta Rasetti1, Venkata S Mattay, Lisa M Wiedholz, Bhaskar S Kolachana, Ahmad R Hariri, Joseph H Callicott, Andreas Meyer-Lindenberg, Daniel R Weinberger.   

Abstract

OBJECTIVE: Although amygdala dysfunction is reported in schizophrenia, it is unknown whether this deficit represents a heritable phenotype that is related to risk for schizophrenia or whether it is related to disease state. The purpose of the present study was to examine amygdala response to threatening faces among healthy siblings of schizophrenia patients in whom a subtler heritable deficit might be observed.
METHOD: Participants were 34 schizophrenia patients, 29 unaffected siblings, and 20 healthy comparison subjects. Blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) was conducted during an implicit facial information processing task. The N-back working memory task, which has been shown to elicit prefrontal cortex abnormalities in unaffected siblings of schizophrenia patients, was employed as a positive experimental control.
RESULTS: Schizophrenia patients demonstrated a deficit in amygdala reactivity to negative face stimuli and an alteration, correlated with neuroleptic drug dosage, in the functional coupling between the amygdala and subgenual cingulate. In contrast, unaffected siblings showed a pattern that was not statistically different from that of healthy comparison subjects. During the N-back working memory task, both schizophrenia patients and their unaffected siblings demonstrated a pattern of inefficient prefrontal cortex engagement, which is consistent with earlier evidence that this pattern is related to genetic risk for schizophrenia.
CONCLUSIONS: These data suggest that the pathophysiological mechanism underlying the inability of individuals with schizophrenia to normally engage the amygdala in processing fearful and angry facial representations is more likely a phenomenon related to the disease state, specifically to treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074979      PMCID: PMC2768494          DOI: 10.1176/appi.ajp.2008.08020261

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  36 in total

1.  Extinction learning in humans: role of the amygdala and vmPFC.

Authors:  Elizabeth A Phelps; Mauricio R Delgado; Katherine I Nearing; Joseph E LeDoux
Journal:  Neuron       Date:  2004-09-16       Impact factor: 17.173

2.  Genetic load on amygdala hypofunction during sadness in nonaffected brothers of schizophrenia patients.

Authors:  Ute Habel; Martina Klein; N Jon Shah; Ivan Toni; Karl Zilles; Peter Falkai; Frank Schneider
Journal:  Am J Psychiatry       Date:  2004-10       Impact factor: 18.112

3.  Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter.

Authors:  Andreas Heinz; Dieter F Braus; Michael N Smolka; Jana Wrase; Imke Puls; Derik Hermann; Sabine Klein; Sabine M Grüsser; Herta Flor; Gunter Schumann; Karl Mann; Christian Büchel
Journal:  Nat Neurosci       Date:  2004-12-12       Impact factor: 24.884

4.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

5.  The assessment and analysis of handedness: the Edinburgh inventory.

Authors:  R C Oldfield
Journal:  Neuropsychologia       Date:  1971-03       Impact factor: 3.139

6.  Genetic risk of neuropsychological impairment in schizophrenia: a study of monozygotic twins discordant and concordant for the disorder.

Authors:  T E Goldberg; E F Torrey; J M Gold; L B Bigelow; R D Ragland; E Taylor; D R Weinberger
Journal:  Schizophr Res       Date:  1995-09       Impact factor: 4.939

7.  Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex.

Authors:  Michael N Smolka; Gunter Schumann; Jana Wrase; Sabine M Grüsser; Herta Flor; Karl Mann; Dieter F Braus; David Goldman; Christian Büchel; Andreas Heinz
Journal:  J Neurosci       Date:  2005-01-26       Impact factor: 6.167

8.  The recognition of facial affect in autistic and schizophrenic subjects and their first-degree relatives.

Authors:  Sven Bölte; Fritz Poustka
Journal:  Psychol Med       Date:  2003-07       Impact factor: 7.723

Review 9.  Learning and memory in monozygotic twins discordant for schizophrenia.

Authors:  T E Goldberg; E F Torrey; J M Gold; J D Ragland; L B Bigelow; D R Weinberger
Journal:  Psychol Med       Date:  1993-02       Impact factor: 7.723

Review 10.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

View more
  37 in total

1.  Polygenic risk for schizophrenia associated with working memory-related prefrontal brain activation in patients with schizophrenia and healthy controls.

Authors:  Karolina Kauppi; Lars T Westlye; Martin Tesli; Francesco Bettella; Christine L Brandt; Morten Mattingsdal; Torill Ueland; Thomas Espeseth; Ingrid Agartz; Ingrid Melle; Srdjan Djurovic; Ole A Andreassen
Journal:  Schizophr Bull       Date:  2014-11-11       Impact factor: 9.306

2.  Amygdala recruitment in schizophrenia in response to aversive emotional material: a meta-analysis of neuroimaging studies.

Authors:  Alan Anticevic; Jared X Van Snellenberg; Rachel E Cohen; Grega Repovs; Erin C Dowd; Deanna M Barch
Journal:  Schizophr Bull       Date:  2010-12-01       Impact factor: 9.306

3.  Facial emotion perception in schizophrenia: Does sex matter?

Authors:  Jasmine Mote; Ann M Kring
Journal:  World J Psychiatry       Date:  2016-06-22

4.  Emotion effects on attention, amygdala activation, and functional connectivity in schizophrenia.

Authors:  Alan Anticevic; Grega Repovs; Deanna M Barch
Journal:  Schizophr Bull       Date:  2011-03-17       Impact factor: 9.306

5.  Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge.

Authors:  Daniel H Wolf; Theodore D Satterthwaite; James Loughead; Amy Pinkham; Eve Overton; Mark A Elliott; Gersham W Dent; Mark A Smith; Ruben C Gur; Raquel E Gur
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

6.  Brain-Wide Functional Dysconnectivity in Schizophrenia: Parsing Diathesis, Resilience, and the Effects of Clinical Expression.

Authors:  Shuixia Guo; Ningning He; Zhening Liu; Zeqiang Linli; Haojuan Tao; Lena Palaniyappan
Journal:  Can J Psychiatry       Date:  2019-11-28       Impact factor: 4.356

7.  Familial Risk and a Genome-Wide Supported DRD2 Variant for Schizophrenia Predict Lateral Prefrontal-Amygdala Effective Connectivity During Emotion Processing.

Authors:  Tiziana Quarto; Isabella Paparella; Davide De Tullio; Giovanna Viscanti; Leonardo Fazio; Paolo Taurisano; Raffaella Romano; Antonio Rampino; Rita Masellis; Teresa Popolizio; Pierluigi Selvaggi; Giulio Pergola; Alessandro Bertolino; Giuseppe Blasi
Journal:  Schizophr Bull       Date:  2018-06-06       Impact factor: 9.306

8.  Genetic variation in CACNA1C affects brain circuitries related to mental illness.

Authors:  Kristin L Bigos; Venkata S Mattay; Joseph H Callicott; Richard E Straub; Radhakrishna Vakkalanka; Bhaskar Kolachana; Thomas M Hyde; Barbara K Lipska; Joel E Kleinman; Daniel R Weinberger
Journal:  Arch Gen Psychiatry       Date:  2010-09

9.  Working Memory in Unaffected Relatives of Patients With Schizophrenia: A Meta-Analysis of Functional Magnetic Resonance Imaging Studies.

Authors:  Ruibin Zhang; Marco Picchioni; Paul Allen; Timothea Toulopoulou
Journal:  Schizophr Bull       Date:  2016-01-05       Impact factor: 9.306

10.  Effect of schizophrenia risk-associated alleles in SREB2 (GPR85) on functional MRI phenotypes in healthy volunteers.

Authors:  Eugenia Radulescu; Fabio Sambataro; Venkata S Mattay; Joseph H Callicott; Richard E Straub; Mitsuyuki Matsumoto; Daniel R Weinberger; Stefano Marenco
Journal:  Neuropsychopharmacology       Date:  2012-09-12       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.